17-Methylestra-1,3,5(10)-trien-3-ol | 59452-14-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 17-Methylestra-1,3,5(10)-trien-3-ol
• 英文别名: 13,17-dimethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-ol
• CAS: 59452-14-1
• 化学式: C₁₉H₂₆O
• 分子量: 270.4
• InChiKey: SVEOBRKOIXNDIJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  20
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Contraception and hormone replacement therapy comprising a combination of estrogene with cholesterol and progesterone
  申请人：Skendi Finance, Ltd.

  公开号：EP1844765A1

  公开（公告）日：2007-10-17

  The invention provides a method for effecting simultaneous contraception and hormone replacement therapy in a female mammal comprising administering to said mammal a pharmaceutical formulation comprising particles of 17-β-estradiol and cholesterol in about a 1:1 molar ratio, and particles of progesterone; wherein the weight ratio of 17-β-estradiol to progesterone is about 1:40.

  本发明提供了一种对雌性哺乳动物同时进行避孕和激素替代治疗的方法，该方法包括向所述哺乳动物施用一种药物制剂，该制剂包括摩尔比约为 1:1 的 17-β-雌二醇和胆固醇颗粒以及黄体酮颗粒；其中 17-β-雌二醇与黄体酮的重量比约为 1:40。
• Anti-scarring drug combinations and use thereof
  申请人：Hunter L. William

  公开号：US20070208134A1

  公开（公告）日：2007-09-06

  The present invention provides devices or implants that comprise anti-scarring drug combinations, methods or making such devices or implants, and methods of inhibiting fibrosis between the devices or implants and tissue surrounding the devices or implants. The present invention also provides compositions that comprise anti-fibrotic drug combinations, and their uses in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.
• FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING
  申请人：Ramachandra Sumant

  公开号：US20110097340A1

  公开（公告）日：2011-04-28

  Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen-binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.
• US8216571B2
  申请人：——

  公开号：US8216571B2

  公开（公告）日：2012-07-10